期刊
NEUROBIOLOGY OF AGING
卷 34, 期 7, 页码 1779-1789出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2013.01.020
关键词
Serotonin; Alzheimer's disease; Mouse model; APP processing; A beta
资金
- Arthur Bax and Anna Vanluffelen chair for Alzheimer's disease
- KNDD (BMBF)
- Shire-Movetis-NV
- IWT [070311, 100551]
- Methusalem grant
Lowering the production and accumulation of A beta has been explored as treatment for Alzheimer's disease (AD), because A beta is postulated to play an important role in the pathogenesis of AD. 5-HT4 receptors are an interesting drug target in this regard, as their activation might stimulate alpha-secretase processing, which increases sAPP alpha and reduces A beta, at least according to the central dogma in APP processing. Here we describe a novel high-affinity 5-HT4 receptor agonist SSP-002392 that, in cultured human neuroblastoma cells, potently increases the levels of cAMP and sAPP alpha at 100-fold lower concentrations than the effective concentrations of prucalopride, a known selective 5-HT4 receptor agonist. Chronic administration of this compound in a hAPP/PS1 mouse model of Alzheimer's disease decreased soluble and insoluble A beta in hippocampus, but the potential mechanisms underlying these observations seem to be complex. We found no evidence for direct alpha-secretase stimulation in the brain in vivo, but observed decreased APP and BACE-1 expression and elevated astroglia and microglia responses. Taken together these results provide support for a potential disease-modifying aspect when stimulating central 5-HT4 receptors; however, the complexity of the phenomena warrants further research. (C) 2013 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据